Olaparib is currently clinically employed in ovarian cancers harboring BRCA1/2 deficiencies [109], and has also begun to show promise in BRCA1/2-deficient chemoresistant, metastatic breast and prostate cancers [110,111]. This evidence concerns the gene BRCA1 and prostate cancer.